Posters

Evaluation of macular tickness after phacoemulsification cataract surgery

Poster Details

First Author: M.Zakoun MOROCCO

Co Author(s): S. Belghmaidi   N. Inzale   R. Oukassou   I. Hajji   A. Moutaouakil        

Abstract Details

Purpose:

The aim of our study is to quantitatively evaluate modifications in macular thickness using optical coherence tomography (OCT) following uncomplicated phacoemulsification cataract surgery with posterior chamber intraocular lens implantation.

Setting:

Ophtalmology Department, University Hospital Mohammed VI, Marrakesh, Morocco

Methods:

This is a prospective study made from January  to August 2019, including patients who had uncomplicated phacoemulsification cataract surgery with posterior chamber intraocular lens implantation. All our patients benefited from an anamnesis, a complete clinical examination and an OCT preoperatively, then at day 7, 1 month and 2 months later. All of them received the same postoperative medication based on non steroid anti-inflammatory drugs, local corticoids and antibiotics. Patients with pre–existing retinal pathology, including  macular degeneration or macular edema and diabetics were excluded.

Results:

124 patients were included.The average age was 68years.The mean preoperative acuity was 1.7/10.The mean duration of the intervention was 16.2 minutes.Phacoemulsification time was about 2min±15.Mean phacoenergy was 37%±12.The mean initial foveal thickness was 202+/-17 um,then reached 237 µm at 1 month following surgery, to decrease to 217±25 at 2 months.The best visual acuity  has increased from 1.7/10 preoperatively to 4/10 at one week to reach 9/10 at 2 months.The central macular thickness at 1 month increased between 10 and 20% in 51 patients and the most involved factor was the duration of the procedure.

Conclusions:

The variations in macular thickness is a commun situation after phacoemulsification surgery. Although these measured changes were statistically significant, visual acuity improved in all patients, indicating minimal effect on clinical outcome.

Financial Disclosure:

None